Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 11/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042880 | 0.89 | P2RX7 (0.40) | P2RX7CNR1CNR2GPR55MEN1 | |
| SCHEMBL20042666 | 0.89 | KMT2A (0.46) | P2RX7CNR1CNR2GPR55MEN1 | |
| SCHEMBL20042823 | 0.88 | P2RX7 (0.45) | P2RX7CNR1CNR2GPR55MEN1 | |
| SCHEMBL20042884 | 0.87 | P2RX7 (0.40) | P2RX7GPR6CNR1CNR2GPR55 | |
| SCHEMBL20042792 | 0.86 | TACR3 (0.46) | P2RX7GPR6CNR1CNR2GPR55 | |
| SCHEMBL20042836 | 0.86 | P2RX7 (0.43) | P2RX7CNR1CNR2GPR55MEN1 | |
| SCHEMBL20042917 | 0.86 | P2RX7 (0.39) | P2RX7GPR6 | |
| SCHEMBL20042696 | 0.84 | KDM1A (0.45) | P2RX7MEN1KMT2A | |
| SCHEMBL20042667 | 0.84 | TACR3 (0.46) | P2RX7TACR3 | |
| SCHEMBL20042685 | 0.83 | HTT (0.42) | P2RX7TACR3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018066718-A1 | THERAPEUTIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-12 | — | — | WO | disclosed |